Channel Wealth LLC Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Channel Wealth LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 144.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,175 shares of the company’s stock after purchasing an additional 23,711 shares during the period. Channel Wealth LLC’s holdings in AstraZeneca were worth $2,632,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. McClarren Financial Advisors Inc. grew its holdings in shares of AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca in the 3rd quarter worth approximately $28,000. Ashton Thomas Securities LLC acquired a new stake in shares of AstraZeneca in the 3rd quarter worth approximately $45,000. Hollencrest Capital Management grew its holdings in shares of AstraZeneca by 38.4% in the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after acquiring an additional 192 shares during the period. Finally, Versant Capital Management Inc grew its holdings in shares of AstraZeneca by 2,618.5% in the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after acquiring an additional 707 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Up 1.9 %

Shares of AstraZeneca stock opened at $66.91 on Friday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The firm has a market cap of $207.46 billion, a PE ratio of 32.01, a P/E/G ratio of 1.05 and a beta of 0.46. The business’s fifty day moving average is $66.06 and its two-hundred day moving average is $74.57. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period last year, the company posted $0.87 EPS. Analysts anticipate that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Wall Street Analyst Weigh In

AZN has been the topic of a number of research reports. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca presently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.